Eloxx Pharmaceuticals (ELOX) risk factors, FY2025 10-K

Risks Related to Our Filing History

1. 01We have been delinquent in our public filing obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and there are no assurances that we will be successful in regaining compliance or, if regained, remaining current in our public filing obligations
2. 02a decreased ability to issue additional securities or obtain additional financing in the future
3. 03Our failure to timely file periodic reports with the SEC could limit our access to the public markets to raise debt or equity capital

Risks Related to Financial Position and Need for Additional Capital

1. 04We are a clinical stage biotechnology company and have incurred significant operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability
2. 05operate as a public company including costs associated with regaining and maintaining Nasdaq compliance
3. 06We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts
4. 07the extent to which we acquire or in-license other product candidates and technologies
5. 08Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern
6. 09Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
7. 10We do not intend to pay dividends for the foreseeable future

Risks Related to Drug Discovery, Development, Regulatory Approval and Commercialization

1. 11We are heavily dependent on the success of our lead product candidate, exaluren. If exaluren does not achieve positive results during development or suffers any material development delays, it may adversely impact the commercial viability of exaluren and our business
2. 12maintaining a continued acceptable safety profile of our products following any approval
3. 13third parties being unwilling or unable to satisfy their contractual obligations to us
4. 14adverse impact on our business, financial condition and prospects. Further, the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates
5. 15We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
6. 16Federal laws that require pharmaceutical manufactures to submit regular reports on drug pricing and price calculation methodologies; and
7. 17Our lead product candidate, including exaluren, may cause adverse events or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance
8. 18Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects
9. 19We may find it difficult to recruit and enroll patients in our clinical trials, which could cause significant delays in the completion of such trials or may cause us to abandon one or more clinical trials
10. 20clinicians’ and patient perception as to the potential advantages of the drug being studied in relation to other available therapies
11. 21We may conduct clinical trials for our product candidates outside of the United States and the FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business
12. 22Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
13. 23The regulatory approval processes of the FDA and comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
14. 24the approval policies or regulations of the FDA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
15. 25Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize such candidates in any other jurisdiction, which would limit our ability to realize their full market potential
16. 26If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any of our product candidates that obtain regulatory approval, we may be unable to generate any revenue
17. 27Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight
18. 28The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
19. 29There is no guarantee that we will receive in a timely fashion or at all the additional milestone or royalty payments under the Almirall License Agreement
20. 30The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
21. 31Developments by competitors may render our product candidates or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition
22. 32If we are unable to develop and commercialize our product candidates, our business will be adversely affected
23. 33the research methodology used may not be successful in identifying potential product candidates; or
24. 34Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
25. 35Our inability to promptly obtain coverage and adequate reimbursement from both third-party payors for the product candidates that we may develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations, and prospects
26. 36establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, including prescription drug spending
27. 37these programs are implemented. The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, but is likely to be significant

Risks Related to Our Business and Operations

1. 38Our business strategy includes expanding our product candidates and capabilities. We regularly evaluate potential merger, acquisition, collaboration and in-license opportunities that we expect will expand our pipeline or product offerings, and enhance our research or development programs
2. 39Our business could be affected by litigation, government investigations and enforcement actions
3. 40We could be subject to additional tax liabilities
4. 41Material weaknesses in our internal control over financial reporting could have a significant adverse effect on our business and the price of our common stock
5. 42Our business could be adversely affected by the effects of widespread public health epidemics and other factors beyond our control
6. 43Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition
7. 44disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business’s behalf. Additional compliance investment and potential business process changes may also be required
8. 45Our business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity
9. 46the misappropriation of our proprietary information, including our trade secrets and know-how
10. 47We have vendors and third party service providers located outside of the United States that subject us to additional risks that are beyond our control and that could harm our business, financial condition, results of operations, and prospects
11. 48Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel
12. 49We have a limited number of employees, which could adversely affect our business and operations
13. 50Our employees and independent contractors, including collaborators, principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
14. 51We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management

Risks Related to Intellectual Property

1. 52If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish, and our business, competitive position and results of operations would suffer
2. 53whether we will need to initiate litigation or administrative proceedings, which may be costly, and whether we win or lose
3. 54If we cannot obtain new patents, maintain our existing patents and protect the confidentiality and proprietary nature of our trade secrets and other intellectual property, our business and competitive position may be harmed
4. 55If we infringe the rights of third parties, we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition
5. 56We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position
6. 57If we cannot meet requirements under our license agreement, we could lose the rights to our product candidates, which could have a material adverse effect on our business
7. 58We may become involved in lawsuits to protect or enforce or defend our intellectual property, which could be expensive, time consuming and unsuccessful and have an adverse effect on the success of our business
8. 59infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible

Risks Related to Our Regional Operations

1. 60Potential political and economic instability in regions where we conduct business may adversely affect our results of operations
2. 61Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. These situations may potentially escalate in the future to more violent events which may affect Israel and us
3. 62We received Israeli government grants for our research and development activities and programs. The terms of such grants may require us, in the future, to pay royalties and under certain circumstances, penalties in addition to payment of royalties
4. 63technology or development outside of Israel. Such approvals may not be granted by the IIA and any conditions imposed may not be acceptable to the Company
5. 64We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business

Risks Related to Our Common Stock

1. 65Our stock price may be volatile, and purchasers of our common stock could incur substantial losses
2. 66We are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
3. 67year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter
4. 68Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
5. 69the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; and
6. 70Our common stock constitutes “penny stock” within the meaning of the rules of the SEC and may be subject to greater opportunity for manipulation
7. 71Maintaining and improving our financial controls and the requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members
8. 72Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations
9. 732018 and future years may be carried forward indefinitely but generally may not be carried back and are only eligible to offset up to a maximum of 80% of taxable income generated in a given year
10. 74Future sales and issuances of our securities or rights to purchase securities, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the prices of our securities to fall
11. 75We could be subject to securities class action litigation
12. 76Changing circumstances and market conditions, some of which may be beyond our control, could impair our ability to access our existing cash and cash equivalents and to timely pay key vendors and others
13. 77Our insurance policies protect us from only some business risks, which will leave us exposed to significant uninsured liabilities
14. 78We are subject to governmental export and import controls, economic sanctions, anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which could harm our business
15. 79Coastlands and Domicilium own prefunded warrants to purchase a significant percentage of our capital stock and have board designation and certain consent rights, which allow them to exert meaningful influence on our company